ASH 2023 | Investigating acquired mutations in patients with R/R CLL who progressed in the ALPINE study
Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the findings of an investigation into acquired mutations in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) who progress following treatment with zanubrutinib or ibrutinib in the Phase III ALPINE study (NCT03734016). Most relapsing patients did not acquire mutations in BTK and PLCG2, which was not expected based on previously published data. Dr Brown outlines some of the potential reasons for this discrepancy. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Loxo/Lilly, Pharmacyclics, Numab Therapeutics, Merck, Grifols Worldwide Operations, Kite, BeiGene, iOnctura, Alloplex Biotherapeutics, Hutchmed, Pfizer, Genentech/Roche, Abbvie, Acerta/AstraZeneca; Research Funding: Loxo/Lilly, TG Therapeutics, Gilead, BeiGene, iOnctura, SecuraBio, MEI Pharma.
